RWJ-270201 BioCryst Pharmaceuticals/Johnson & Johnson.
RWJ-270201, the lead compound in a series of influenza neuraminidase inhibitors, is under development by BioCryst for the potential treatment of influenza [214908], [337716]. Phase III trials commenced in North America and Europe in February 2000 [355053]. Phase II studies were performed to test the effectiveness of RWJ-270201 at reducing viral titers in infected patients. Data showed that the compound was well tolerated and produced statistically significant reductions in viral titers [337716]. Under a worldwide influenza collaboration formed in September 1998, two subsidiaries of Johnson & Johnson, the RW Johnson Pharmaceutical Research Institute and Ortho McNeil, have received exclusive worldwide rights to RWJ-270201 [298487].
Barnard
D L
DL
Utah State University, Institute for Antiviral Research, 5600 Old Main Hill, Logan, UT 84322-5600, USA. honery@cc.usu.edu
D000146:Acids, Carbocyclic; D000818:Animals; D000998:Antiviral Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D002986:Clinical Trials as Topic; D003517:Cyclopentanes / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D015507:Drugs, Investigational / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D006146:Guanidines; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy*; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
D000146:Acids, Carbocyclic; D000998:Antiviral Agents; D003517:Cyclopentanes; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D006146:Guanidines; D009439:Neuraminidase; C414210:peramivir